Table 1 Baseline Demographics.
Baseline Characteristics | Total (n = 26) | Newly diagnosed n = 7 | Relapsed/refractory n = 19 |
|---|---|---|---|
Age (years) | 68 (24–88) | 77 (66–81) | 64 (24–88) |
Sex (male) | 20 (84) | 6 (86) | 14 (82) |
Performance status | |||
ECOG 0 | 1 (4) | 1 (14) | 0 |
ECOG 1 | 18 (69) | 4 (57) | 14 (74) |
ECOG ≥ 2 | 7 (28) | 2 (29) | 5 (26) |
Hematological parameters | |||
Hemoglobin (mg/dL) | 8.6 (6.2–13.7) | 8.4 (6.2–10.6) | 8.8 (7.1–13.7) |
White Blood Count, x109/L | 3.8 (0.4–270) | 6 (2–270) | 1.5 (0.4–36) |
Platelet, x109/L | 52 (12–1145) | 74 (30–1145) | 30 (12–223) |
Circulating blasts (%) | 20 (0–95) | 34 (10–95) | 5 (0–66) |
Bone marrow blasts (%), | 39 [4–87] | 57 [20–86] | 20 [4–87] |
ELN 2017 risk group | |||
Intermediate | 14 (59) | 5 (71) | 9 (47) |
Adverse | 12 (41) | 2 (29) | 10 (53) |
Diagnosis | |||
In first relapse | 0 | 8(42) | |
In second or later relapse | 0 | 11 (58) | |
Prior AML therapies | |||
HMA | 9 (28) | 1 (14) | 9 (42) |
ENA | 3 (12) | 3 (16) | |
HSCT | 5 (19) | 5 (26) | |
Co-occurring mutations | |||
ASXL1 | 5 (19) | 2 (29) | 3 (16) |
DNMT3A | 8 (31) | 2 (29) | 6 (31) |
FLT3 | 3 (12) | 2 (29) | 1 (5) |
NPM1 | 5 (19) | 1 (14) | 4 (21) |
(K/N) RAS | 3 (12) | 0 | 3 (16) |
RUNX1 | 6 (23) | 2 (29) | 4 (21) |
SRSF2 | 10 (38) | 5 (71) | 5 (26) |
TET2 | 5 (19) | 1 (14) | 4 (21) |
TP53 | 2 (8) | 0 | 2 (11) |
